Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer

Anticancer Research

Volumn 30, Issue 5, 2010, Pages 1855-1862

  Holdenrieder, Stefan ^a   Von Pawel, Joachim ^b   Duell, Thomas ^b   Feldmann, Knut ^b   Raith, Hannelore ^b   Schollen, Annette ^a   Nagel, Dorothea ^a   Stieber, Petra ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Asklepios Lung Hospital   (Germany)

Author keywords

Biomarker; Lung cancer; Serum; Thymidine kinase; Tumor marker

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; NEURON SPECIFIC ENOLASE; PROGASTRIN RELEASING PEPTIDE; THYMIDINE KINASE;

CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; LUNG DISEASE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; RADIOIMMUNOASSAY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; FEMALE; HUMANS; KERATIN-19; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHOPYRUVATE HYDRATASE; PROGNOSIS; RADIOIMMUNOASSAY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77954572689     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics 2007. CA Cancer J Clin 57: 43-66, 2007.
2. Mountain CF: The international system for staging lung cancer. Semin Surg Oncol 18: 106-115, 2000. (Pubitemid 30090451)
3. Ettinger DS, Bepler G, Bueno R, Chang A, Chang JY, Chirieac LR, D'Amico TA, Demmy TL, Feigenberg SJ, Grannis FW Jr, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CJ, Le QT, Martins R, Otterson GA, Robert F, Sugarbaker DJ and Wood DE; National Comprehensive Cancer Network (NCCN): Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Cane Netw 4: 548-582, 2006.
4. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT and Somerfield MR: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22: 330-353, 2004.
5. Spira A and Ettinger DS: Multidisciplinary management of lung cancer. N Engl J Med 350: 379-392, 2004.
6. Johnson BE, Crawford J, Downey RJ, Ettinger DS, Fossella F, Grecula JC, Jahan T, Kalemkerian GP, Kessinger A, Koczywas M, Langer CJ, Martins R, Marymont MH, Niell HB, Ramnath N, Robert F and Williams CC Jr; National Comprehensive Cancer Network (NCCN): Small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 4: 602-622, 2006.
7. Stupp R, Monnerat C, Turrisi AT 3rd, Perry MC and Leyvraz S: SCLC: state of the art and future perspectives. Lung Cancer 45: 105-117, 2004.
8. Flieder DB: Commonly encountered difficulties in pathologic staging of lung cancer. Arch Pathol Lab Med 131: 1016-1026, 2007.
9. Schalhorn A, Furst H and Stieber P: Tumor markers in lung cancer. J Lab Med 25: 353-361, 2001.
10. Molina R, Filella X, Auge JM, Fuentes R, Bover I, Rifa J, Moreno V, Canals E, Vinolas N, Marquez A, Barreiro E, Borras J and Viladiu P: Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol 24: 209-218, 2003.
11. Barak V, Goike H, Panaretakis KW and Einarsson R: Clinical utility of cytokeratins as tumor markers. Clin Biochem 37: 529-540, 2004.
12. Stieber P, Hatz R, Holdenrieder S, Molina R, Nap M, von Pawel J, Schalhorn A, Schneider J and Yamaguchi K: National Academy of Clinical Biochemistry Guidelines for the use of tumor markers in lung cancer: In: NACB: Practice Guidelines and Recommendations for Use of Tumor Markers in the Clinic-Lung Cancer 2006; publ. online at www.nacb.org/lmpg/tumor-LMPG-draft-PDF. stm
13. Stieber P, Hasholzner U, Bodenmueller H, Nagel D, Sunder-Plassmann L, Dienemann H, Meier W and Fateh-Moghadam A: CYFRA 21-1. A new marker in lung cancer. Cancer 72: 707-713, 1993.
14. Ebert W, Dienemann H, Fateh-Moghadam A, Scheuten M, Konietzko N, Schleich T and Bombardieri E: Cytokeratin 19 fragments CYFRA 21-1 compared with CEA, SCC antigen and NSE in lung cancer. Results of an international multicentre study. Eur Clin Chem Clin Biochem 32: 189-199, 1994.
15. Kulpa J, Wojcik E, Reinfuss M and Kolodziejski L: CEA, SCC, CYFRA 21-1 and NSE in SCLC patients. Clin Chem 48: 1931-1937, 2002.
16. Molina R, Agusti C, Filella X, Jo J, Joseph J, Gimenez N and Ballesta AM: Study of a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases. Tumour Biol 15: 318-325, 1994. (Pubitemid 24369415)
17. Yamaguchi K, Aoyagi K, Urakami K, Futukani T, Maki N, Yamamoto S, Otsubo K, Myake Y and Kodoma T: Enzyme-linked immunsorbent assay of ProGRP for SCLC patients in comparison with NSE measurement. Jpn J Cancer Res 86: 698-705, 1995.
18. Stieber P, Dienemann H, Schalhorn A, Schmitt UM, Reinmiedl J, Hofmann K and Yamaguchi K: Pro-gastrin-releasing peptide (ProGRP) - a useful marker in small cell lung carcinomas. Anticancer Res 19: 2673-2678, 1999.
19. Molina R, Filella X and Auge JM: ProGRP: a new biomarker for small cell lung cancer. Clin Biochem 37: 505-511, 2004. (Pubitemid 38845013)
20. Molina R, Auge JM, Filella X, Viñolas N, Alicarte J, Domingo JM and Ballesta AM: Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. Anticancer Res 25: 1773-1778, 2005.
21. Schneider J, Philipp M, Velcovsky HG, Morr H and Katz N: Progastrin-releasing peptide (ProGRP), neuron-specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19 fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases. Anticancer Res 23: 885-893, 2003.
22. Gronowitz JS, Steinholtz L, Kallander CF, Hagberg H and Bergh J: Serum deoxythymidine kinase in small cell carcinoma of the lung. Relation to clinical features, prognosis, and other biochemical markers. Cancer 58: 111-118, 1986.
23. Gronowitz JS, Bergstrom R, Nou E, Pahlman S, Brodin O, Nilsson S and Kallander CF: Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis. Cancer 66: 722-732, 1990.
24. Li HX, Lei DS, Wang XQ, Skog S and He Q: Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer. Oncol Rep 13: 145-149, 2005.
25. van der Gaast A, van Putten WL, Oosterom R, Cozijnsen M, Hoekstra R and Splinter TA: Prognostic value of serum thymidine kinase, tissue polypeptide antigen and neuron specific enolase in patients with small cell lung cancer. Br J Cancer 64: 369-372, 1991.
26. Hallek M, Wanders L, Strohmeyer S and Emmerich B: Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications. Ann Hematol 65: 1-5, 1992.
27. Fischbach W, Schwarz-Wallrauch C and Jany B: Neuron-specific enolase and thymidine kinase as an aid to the diagnosis and treatment monitoring of small cell lung cancer. Cancer 63: 1143-1149, 1989. (Pubitemid 19074745)
28. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
29. Anonymous: Tumour markers in lung cancer: EGTM recommendations. Anticancer Res 19: 2817-2819, 1999.